All episodes

 In this podcast, the authors reviewed and discussed seven abstracts presented at the 65th Annual Meeting of the American Society of Hematology, focusing on B cell maturation antigen-directed therapies, emphasizing the value of real-world data (RWD) in treatment decision-making, and suggesting how RWD can help advance multiple myeloma research. These abstracts include real-world outcome studies in patients with relapsed or refractory multiple myeloma with triple-class exposed or refractory disease (abstracts 542, 3358, and 6727); an analysis on disease burden associated with delayed diagnosis (abstract 3771); comparability of real-world outcomes vs clinical trial data (abstracts 91 and 545); and outcomes in...

Chimeric antigen receptor T cell (CAR-T) therapies targeting the CD19 antigen have been associated with high and durable response rates in patients with diffuse large B cell lymphoma (DLBCL). In this podcast, Dr. Foley and Dr. Kuruvilla discuss the case of a patient presenting with the ideal profile for CAR-T cell therapy referral whilst also determining the key attributes for eligibility from a clinician’s perspective. Solutions for successful outpatient management include proper education, caregiver support, and early referral to ensure a timely infusion. In conclusion, outpatient administration of CAR-T cell therapy in patients with DLBCLs should be assessed on a...

Panel-based sequencing platforms are becoming more accessible, and molecular biomarker analysis of circulating tumor DNA is becoming more common. In this podcast, authors discuss the importance of biomarker testing in advanced non-small cell lung cancer (NSCLC) and explore topics such as testing methodologies, effect of biomarker testing on patient outcomes, emerging technologies, and strategies for improving testing rates in the United States. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00271-w. All conflicts of interest...

In this podcast the Chair and Secretary of the 2023 International Working Group on the Diabetic Foot (IWGDF) guideline on offloading treatments for diabetes-related foot ulcers briefly discuss why we need offloading treatments for people with diabetes-related foot ulcers, what the new international offloading guideline recommends, and where offloading treatment might go into the future.   This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the Diabetes Therapy website and by using this link: https://link.springer.com/article/10.1007/s13300-023-01522-1. All conflicts of interest can be found online.   Open Access This podcast is...

In this podcast, the Chair and Secretary of the 2023 update of the International Working Group of the Diabetic Foot (IWGDF) guidelines on Classification discuss the results of update to the guidelines addressing the use of systems to classify foot ulcers in people with diabetes in routine clinical practice.   This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the Diabetes Therapy website and by using this link: https://link.springer.com/article/10.1007/s13300-023-01521-2. All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons...

Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment option. However, disease progression inevitably occurs, driven by EGFR-dependent or EGFR-independent mechanisms of resistance. Platinum-based chemotherapy is the recommended treatment following progression with osimertinib but responses to platinum-based chemotherapy are transient. Salvage therapies, which are used after progression on platinum-based chemotherapy, have poor clinical outcomes in addition to substantial toxicity. In this podcast, authors discuss the current treatment landscape and emerging therapeutic options for patients with metastatic EGFR-mutated NSCLC whose disease has progressed following treatment with osimertinib and platinum-based chemotherapy....

In this podcast, authors discuss how to ensure that individual patients’ needs and concerns are addressed when it comes to shared decision-making on treatment for metastatic breast cancer. Including an overview of different approaches for initial consultations, strategies for tailoring conversations based on a patient’s background or health literacy, and trustworthy resources that can help improve patients’ understanding. As an illustrative example, authors focus on how to implement shared decision-making to address the needs of a patient with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer who is eligible for combination therapy with a cyclin-dependent kinase...

Authors Dr Peter Black and Dr Bernie Eigl aim to provide an overview of the non-muscle-invasive bladder cancer (NMIBC) landscape with a focus on high-risk NMIBC. This includes understanding the diagnosis and current treatment approaches with a focus on the medical needs and high-risk NMIBC treatment, highlighting the potential challenges associated with the introduction of programmed cell death ligand 1 (PD-(L)1) therapies in NMIBC. And then provide insights into the patient journey within the institution and its translation into practical settings. Finally, the authors explore future outlooks and directions for PD-(L)1 use in NMIBC treatment. This podcast is published open...

In this podcast, author Dr Kai Hübel discussed a case of a patient with high-risk relapse follicular lymphoma. This discussion outlines the potential effectiveness of chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory follicular lymphoma. This podcast is adapted from a vodcast article published open access in Oncology and Therapy and is fully citeable. The vodcast article features the same audio, but is accompanied by slides and author video. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this...

In this podcast, Elias Jabbour from the University of Texas MD Anderson Cancer Center, Houston, TX, and Matthias Stelljes from the Universitätsklinikum Münster, Münster, Germany summarize and highlight some of the recent findings on the use of inotuzumab ozogamicin as induction therapy for older adults with newly diagnosed acute lymphoblastic leukemia (ALL). This peer-reviewed podcast is published open access in Targeted Oncology and is fully citable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-023-01023-y All conflicts of interest can be found online. Open Access: This podcast is licensed under...